Progenics Pharmaceuticals, Inc.
(NASDAQ : PGNX)

( )
PGNX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.36%352.430.0%$5529.05m
BNTXBioNTech SE -2.97%351.740.0%$1554.09m
NVAXNovavax, Inc. 7.56%208.6378.2%$1149.83m
AMGNAmgen, Inc. -2.26%198.881.4%$591.30m
LGVNLongeveron Inc. 0.04%26.260.0%$511.78m
GILDGilead Sciences, Inc. -2.44%68.931.0%$497.91m
REGNRegeneron Pharmaceuticals, Inc. -2.73%636.532.7%$490.45m
VRTXVertex Pharmaceuticals, Inc. -1.67%186.941.9%$375.32m
SNSSSunesis Pharmaceuticals, Inc. 0.88%4.610.7%$322.26m
ILMNIllumina, Inc. -1.48%365.333.3%$311.28m
OCGNOcugen, Inc. -1.40%6.340.0%$293.70m
BIIBBiogen, Inc. -0.16%235.741.8%$289.61m
EXASEXACT Sciences Corp. -1.39%85.3718.0%$167.68m
INCYIncyte Corp. -3.77%67.722.4%$165.57m
BMRNBioMarin Pharmaceutical, Inc. -1.27%86.294.2%$144.64m

Company Profile

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.